SWOG S2213 AL Amyloidosis - Clinical Trial
Who Can Participate in the Study?
Age Group
Adults
Study Details
Full Title
S2213: A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis
Principal Investigator
Hematologic Oncologist
Protocol Number
IRB:
PRO00115899
NCT:
NCT06022939
Phase
Phase
III
ClinicalTrials.gov
View on ClinicalTrials.gov
Enrollment Status
Open for Enrollment